BioAtla (NASDAQ:BCAB) Price Target Cut to $7.00 by Analysts at HC Wainwright

BioAtla (NASDAQ:BCAB) had its price target reduced by HC Wainwright from $10.00 to $7.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Separately, JMP Securities reiterated a market outperform rating and set a $12.00 price target on shares of BioAtla in a research report on Tuesday, December 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BioAtla presently has an average rating of Buy and a consensus target price of $14.20.

BioAtla Price Performance

Shares of BCAB stock opened at $3.46 on Wednesday. BioAtla has a 12 month low of $1.24 and a 12 month high of $4.07. The company has a market capitalization of $165.87 million, a PE ratio of -1.30 and a beta of 1.02. The firm’s 50-day moving average is $2.47 and its two-hundred day moving average is $2.08.

Institutional Trading of BioAtla

Several institutional investors have recently modified their holdings of BCAB. BlackRock Inc. lifted its position in shares of BioAtla by 225.2% during the 2nd quarter. BlackRock Inc. now owns 3,198,782 shares of the company’s stock worth $9,596,000 after buying an additional 2,215,270 shares during the last quarter. Soleus Capital Management L.P. raised its position in BioAtla by 24.1% in the 4th quarter. Soleus Capital Management L.P. now owns 4,220,397 shares of the company’s stock valued at $34,818,000 after purchasing an additional 819,894 shares during the last quarter. Wasatch Advisors LP raised its position in BioAtla by 119.0% in the 1st quarter. Wasatch Advisors LP now owns 1,268,169 shares of the company’s stock valued at $3,399,000 after purchasing an additional 689,193 shares during the last quarter. State Street Corp raised its position in BioAtla by 434.7% in the 2nd quarter. State Street Corp now owns 712,269 shares of the company’s stock valued at $2,137,000 after purchasing an additional 579,063 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in BioAtla in the 1st quarter valued at $1,373,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.